

# **Institutional Review Board**

**Investigator Guidance Series** 

# **Continuing Review (HRPP 2.7)**

## **Description:**

This policy describes UNMC's requirements for continuing review of approval research.

#### **Definitions:**

<u>Continuing Review of Research:</u> the process by which the IRB re-evaluates whether a protocol continues to satisfy the regulatory and ethical criteria for approval.

#### **Continuing Review REQUIRED for:**

- Research which was reviewed by the convened IRB (has "FB" suffix for the IRB number).
- Research that is regulated by the FDA.
- Research that underwent expedited review (has "EP" suffix for the IRB number) that was approved prior to January 20, 2019.

#### **Continuing Review NOT REQUIRED for:**

- Research that underwent expedited review on or after January 20, 2019 that is not subject to FDA regulations, unless the IRB determines otherwise.
- Exempt research (has "EX" suffix for the IRB number) unless the ORA determines otherwise.

There are exceptions to our policy. You will be notified by the IRB/ORA prior to the deadline for continuing review if your research needs it.

.



#### Frequency:

#### Non-exempt research subject to the Common Rule or FDA Regulations:

Once a year (unless the IRB determines it's needed more often).

## Non-exempt research NOT subject to the Common Rule or FDA Regulations:

Intervals are selected based on the degree of risk, but typically once a year.

#### **Review Criteria:**

- All criteria for IRB approval (HRPP Policy 2.5).
- In addition, the IRB (full IRB or expedited reviewer) must also determine:
  - Whether continuing review should occur more often than annually.
  - Whether the research needs verification from sources other than the PI that no material changes occurred.
  - Whether the current consent form is still accurate and complete.
  - Whether the research requires an audit of the research records.
  - Whether any new findings arise that might relate to a subject's willingness to continue participating.
  - Whether subject accrual is adequate to achieve the scientific goals.
- During continued review by an expedited reviewer, if the reviewer believes any of the above situations apply, the protocol will be referred to the full IRB.

# **Investigator Responsibilities:**

- Submit a continuing review form in RSS prior to the expiration date of the approved protocol.
  - For most full board (FB) studies, HUD studies, or SROC studies, you must submit enough in advance that the continuing review can be reviewed at a convened IRB meeting before the expiration date (see <a href="https://www.unmc.edu/irb/procedures/deadlines.htm">https://www.unmc.edu/irb/procedures/deadlines.htm</a> for deadlines).
- If the research is completed, complete the closure of on-going research process prior to the approval expiration date. (HRPP Policy 2.9).

#### **General Considerations:**

- The ORA sends emails to the PI and lead coordinator and/or regulatory contact approximately 60 days and 45 days prior to expiration.
- If continuing review is not approved by the expiration date, the study will be expire and all research activities, including data analysis, must cease.
- Studies that continue in "approval expired" status for 30 days may be administratively closed by the IRB/ORA.
- The expiration date for the next continuing review is based on the date that the IRB reviewed the continuing review and either approved or conditionally approved the continuing review.